Adults (18-65), Geriatrics (65+)
Adults (18-65), Geriatrics (65+)
Not accepting new patients
Pulmonary Disease, 2003
Perelman Center for Advanced Medicine
West Pavilion, 1st Floor
3400 Civic Center Boulevard
Philadelphia, PA 19104
A facility of the Hospital of the University of Pennsylvania
The Patient Satisfaction Rating is an average of all responses to the care provider related questions shown below from our nationally-recognized Press Ganey Patient Satisfaction Survey. Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.
Responses are measured on a scale of 1 to 5 with 5 being the best score.
Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.
Rendle KA, Burnett-Hartman AN, Neslund-Dudas C, Greenlee RT, Honda S, Elston Lafata J, Marcus PM, Cooley ME, Vachani A, Meza R, Oshiro C, Simoff MJ, Schnall MD, Beaber EF, Doria-Rose VP, Doubeni CA, Ritzwoller DP: Evaluating Lung Cancer Screening Across Diverse Healthcare Systems: A Process Model from the Lung PROSPR Consortium Cancer Prev Res : 2020.
Silvestri GA, Bevill BT, Huang J, Brooks M, Choi Y, Kennedy G, Lofaro L, Chen A, Rivera MP, Tanner NT, Vachani A, Yarmus L, Pastis NJ: An evaluation of diagnostic yield from Bronchoscopy: the impact of clinical/radiographic factors, procedure type and degree of suspicion for cancer Chest : 2020.
Yarmus L, Akulian J, Wahidi M, Chen A, Steltz JP, Solomon SL, Yu D, Maldonado F, Cardenas-Garcia J, Molena D, Lee H, Vachani A: A Prospective Randomized Comparative Study of Three Guided Bronchoscopic Approaches for Investigating Pulmonary Nodules: The PRECISION-1 Study Chest : 2019 (epub ahead of print).
Bagley SJ, Talento S, Mitra N, Meropol NJ, Cohen RB, Langer CJ, Vachani A: Comparative Effectiveness of Carboplatin-Pemetrexed With vs Without Bevacizumab in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer Journal of the National Comprehensive Cancer Network 15 (5): 469-477,2019.
Thompson JC, Fan R, Black T, Yu GH, Savitch SL, Chien A, Yee SS, Sen M, Hwang WT, Katz SI, Feldman M, Vachani A, Carpenter EL.: Measurement and immunophenotyping of pleural fluid EpCAM-positive cells and clusters for the management of non-small cell lung cancer patients. Lung Cancer 127 : 25-33,2019.
Kossenkov AV, Qureshi R, Dawany NB, Wickramasinghe J, Liu Q, Majumdar RS, Chang C, Widura S, Kumar T, Horng WH, Konnisto E, Criner G, Tsay JJ, Pass H, Yendamuri S, Vachani A, Bauer T, Nam B, Rom WN, Showe MK, Showe LC: A Gene Expression Classifier from Whole Blood Distinguishes Benign from Malignant Lung Nodules Detected by Low-Dose CT Cancer Research 79 (1): 263-73,2019.
Weng L, Guo L, Vachani A, Mesaros C, Blair IA.: Quantification of Serum High Mobility Group Box 1 by Liquid Chromatography/High-Resolution Mass Spectrometry: Implications for Its Role in Immunity, Inflammation, and Cancer Anal Chem 90 (12): 7552-7560,2018.
Silvestri GA, Tanner NT, Kearney P, Vachani A, Massion PP, Porter A, Springmeyer SC, Fang KC, Midthun D, Mazzone PJ; PANOPTIC Trial Team: Assessment of Plasma Proteomics Biomarker's Ability to Distinguish Benign From Malignant Lung Nodules: Results of the PANOPTIC (Pulmonary Nodule Plasma Proteomic Classifier) Trial Chest : 2018.
Morris S, Vachani A, Pass HI, Rom WN, Ryden K, Weiss GJ, Hogarth DK, Runger G, Richards D, Shelton T, Mallery DW: Whole blood FPR1 mRNA expression predicts both non-small cell and small cell lung cancer Int J Cancer : 2018.
Huang J., Liu Y., Vitale S., Penning T.M., Whitehead A.S., Blair I.A., Vachani A., Clapper M., Muscat J.E., Lazarus P., Scheet P., Moore J.H., Chen Y.: On meta- and mega-analyses for gene–environment interactions Genetic Epidemiology : 2017.
Pulmonary, Allergy, and Critical Care DivisionUniversity of Pennsylvania School of MedicineSuite 216, Stemmler Hall3450 Hamilton Walk
Phone: (215) 573-7931
Patient appointments: 800-789-7366
Proton therapy is a non–invasive, incredibly precise cancer treatment that uses a beam of protons moving at very high speeds to destroy cancer cells.
Our experienced cancer nurses and referral staff are here to help. Call 800-789-7366 (PENN) or complete an online request.
Learn more about the benefits of translational research at Penn Medicine.